Patents Assigned to Inserm
-
Publication number: 20240002521Abstract: Novel anti-human CD25 antibodies and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or an antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof.Type: ApplicationFiled: November 19, 2021Publication date: January 4, 2024Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, ALDERAAN BIOTECHNOLOGY, UNIVERSITE D'AIX MARSEILLE, UNIVERSITÉ PARIS CITÉ, UNIVERSITE PARIS EST CRETEIL VAL DE MARNEInventors: Daniel OLIVE, Armand BENSUSSAN, Jérôme GIUSTINIANI, Anne MARIE-CARDINE, Amaud FOUSSAT, Jemila HOUACINE
-
Patent number: 11857532Abstract: Friedreich ataxia (FRDA) is caused by a GAA repeat expansion in FXN gene that encodes a mitochondrial protein, frataxin, involved in iron sulfur complex (ISC) assembly. Frataxin deficiency results in abnormal ISC containing proteins, namely respiratory chain complex I-III and aconitases and accumulation of iron in brain and heart of patients. Here, the inventors show that FRDA fibroblasts are unable to limit iron uptake inducing a massive cytosolic iron accumulation and to a lesser extent in mitochondria. The inventors also observed increased transferrin receptor (TfR1) steady state levels and membrane TfR1 accumulation that they ascribed to impaired post-translational modification by palmitoylation as well as delayed transferrin recycling. Finally, the inventors showed that artesunate, dichloroacetate and Coenzyme-A improved TfR1 palmitoylation and thus represent candidate molecules for the treatment of patients with Friedreich ataxia.Type: GrantFiled: December 27, 2019Date of Patent: January 2, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)Inventors: Anne Agnès Rotig, Arnold Munnich, Floriane Petit
-
Patent number: 11852704Abstract: The present disclosure is directed to a motor for a magnetic resonance (MR) tomography room, to a patient table for the MR room, to a MR elastography device, and to a MR tomography device. A MR tomography device for a MR elastography imaging protocol is arranged within the MR tomography room, and includes a rotational drive for supplying rotational energy to power a MR elastography transducer usable during the MR elastography imaging protocol, and a support structure. The rotational drive comprises a terminal for connecting the MR elastography transducer to the rotational drive, and a bearing means configured such that the position of the terminal relative to the support structure is adaptable along a trajectory predetermined by the bearing means. The rotational drive is mounted to the support structure via the bearing means.Type: GrantFiled: March 17, 2022Date of Patent: December 26, 2023Assignees: Siemens Healthcare GmbH, Centre National de la Recherche Scientifique (CNRS), Institut National de La Sante et de la Recherche Medicale (INSERM), King's College London, Department of Health and Human Services, UNIV PARIS XIII PARIS-NORD VILLETANEUSE, Universite de ParisInventors: Giacomo Annio, Verena Muller-Reinwald, Ralph Sinkus, Omar Darwish, Wilfried Schnell, Tamara Elisabeth Falkner, Ahmed M. Gharib
-
Publication number: 20230393152Abstract: An identification of novel combinations of specific metabolites for neurodegenerative diseases for use as biomarkers in the early diagnosis of neurodegenerative diseases.Type: ApplicationFiled: November 18, 2021Publication date: December 7, 2023Applicants: UNIVERSITE GRENOBLE ALPES, INSERM - Institut National de la Santé et de la Recherche MédicaleInventors: Sabrina BOULET, Florence FAUVELLE, David MALLET
-
Publication number: 20230384312Abstract: A method of predicting the risk of recurrence in a subject undergoing treatment for, or having undergone treatment for, clear cell renal cell carcinoma (ccRCC), by comparing the level of extracellular vesicles, preferably microvesicles, expressing carbonic anhydrase 9 (CA9+ MVs) in a sample from the subject with a reference level. Also, a method of diagnosing ccRCC or identifying a risk of developing ccRCC, by comparing the level of CA9+ MVs in a sample from the subject with a reference level.Type: ApplicationFiled: October 22, 2021Publication date: November 30, 2023Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS, UNIVERSITE D'ANGERS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Maria del Carmen MARTINEZ, Pierre BIGOT, Luisa VERGORI
-
Publication number: 20230382991Abstract: An antagonist antibody, or an antigen binding fragment thereof, binds both to human and macaque LILRB1 and/or LILRB2, and has diagnostic and therapeutic uses.Type: ApplicationFiled: October 12, 2021Publication date: November 30, 2023Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE PARIS SACLAY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Benoit FAVIER, Sixtine COINDRE, Anne WIJKHUISEN, Stéphanie SIMON, Roger LE GRAND, Olivier LAMBOTTE
-
Patent number: 11827637Abstract: The present invention concerns a compound of formula (I): or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.Type: GrantFiled: January 13, 2023Date of Patent: November 28, 2023Assignees: AGV Discovery, Institut National de la Sante et de la Recherche Medicale (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Université De MontpellierInventors: Cédric Bories, Loïc Mathieu, Jean-François Guichou, Muriel Gelin, Aurélien Biechy
-
Patent number: 11827747Abstract: The present invention concerns a polymer comprising repetitive units having the following formula (I) wherein R1 is H or Me; L is a linker; R2 is the side chain of an ?-amino acid being other than arginine; m is 0 or an integer comprised from 1 to 10; n is an integer comprised from 1 to 10; and X— is a counterion.Type: GrantFiled: May 6, 2020Date of Patent: November 28, 2023Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITÉ DE STRASBOURGInventors: Fouzia Boulmedais, Delphine Chan-Seng, Nicolas Zydziak, Philippe Lavalle
-
Publication number: 20230372416Abstract: A combination of agents capable of binding an infectious agent, such as an antibody, an antibody derivative, or an antibody mimetic, and immunomodulatory agents, such as probiotic strains, for the treatment or prevention of respiratory infections, in particular bacterial respiratory infections. The agents capable of binding an infectious agent are administered by inhalation.Type: ApplicationFiled: October 8, 2021Publication date: November 23, 2023Applicants: UNIVERSITÉ DE TOURS, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Nathalie HEUZE-VOURC'H, Thomas SECHER, Muriel THOMAS
-
Patent number: 11820813Abstract: The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer.Type: GrantFiled: August 17, 2020Date of Patent: November 21, 2023Assignees: INSERM (INSITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTESInventor: Patricia Forgez
-
Patent number: 11819492Abstract: The present invention relates to a compound of the following general formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.Type: GrantFiled: December 10, 2021Date of Patent: November 21, 2023Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Sorbonne Universite, Universite de Poitiers, Centre Hospitalier Universitaire de PoitiersInventors: Stéphane Bach, Marie-Thérèse Dimanche-Boitrel, Claire Delehouze, Thierry Hauet
-
Patent number: 11823799Abstract: The present invention provides a powerful tool to identify personalized therapeutic strategies. In particular, the invention provides methods for determining therapeutically targetable dominant signaling pathways in a cancer sample from a subject affected with a solid cancer, determining a treatment protocol for the subject, selecting a subject for a therapy, determining whether the subject is susceptible to benefit from a therapy, predicting clinical outcome of the subject, treating the subject and/or predicting the sensitivity of a solid cancer to a therapy.Type: GrantFiled: November 21, 2016Date of Patent: November 21, 2023Assignees: UNIVERSITE DE STRASBOURG, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Dominique Bagnard, Aurore Fernandez, Laurent Jacob, Justine Fritz
-
Patent number: 11820726Abstract: Motuporamine agents having antimicrobial activity and uses thereof.Type: GrantFiled: July 13, 2020Date of Patent: November 21, 2023Assignees: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC., INSERM TRANSFERT, S.A.Inventors: Otto Phanstiel, IV, Jean-Michel Brunel
-
Publication number: 20230364232Abstract: An immunogenic product including at least one immunoglobulin or fragment thereof conjugated with a carrier protein, wherein the at least one immunoglobulin is IgE and preferably wherein the IgE fragment includes the IgE C?3 domain, and wherein the carrier protein is preferably CRM197. Also the use of this immunogenic product for treating inflammatory disorders, and in particular allergic disorders.Type: ApplicationFiled: September 17, 2021Publication date: November 16, 2023Applicants: NEOVACS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT PASTEURInventors: Laurent REBER, Pierre BRUHNS, Eva CONDE GARCIA, Marija BACKOVIC, Vincent SERRA, Géraldine GROUARD-VOGEL, Romain BERTRAND
-
Patent number: 11814685Abstract: This invention relates to a method for diagnosing and/or prognosticating HER2-dependent cancer in a subject, comprising a) measuring the amount of one or more miRNA selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29a-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-3p and miRNA 542-5p in a sample from the subject; b) comparing the amount of one or more miRNA measured in step a) to a reference value; c) finding a deviation or no deviation of the amount of one or more miRNA measured in step a) from the reference value; and d) attributing said finding of deviation or no deviation to a particular diagnosis and/or prognosis of HER2-dependent cancer in the subject.Type: GrantFiled: October 24, 2018Date of Patent: November 14, 2023Assignees: UNIVERSITÉ PARIS CITÉ, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: Sandrine Bourdoulous, Anaïs Domingot, Camille Faure
-
Patent number: 11814683Abstract: Some embodiments are directed to a prognostic method for determining whether a subject is at risk of having the CLAD, comprising: measuring the expression level of POU2AF1 or BLK in a biological sample obtained from the subject; comparing the expression level of POU2AF1 or BLK with a predetermined reference value and concluding that the subject is at risk of having CLAD when the expression level of POU2AF1 or BLK is lower than the predetermined reference value.Type: GrantFiled: March 9, 2021Date of Patent: November 14, 2023Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique, Université de Nantes, Centre Hospitalier Universitaire de NantesInventors: Pierre-Joseph Royer, Antoine Magnan, Sophie Brouard, Richard Danger
-
Publication number: 20230348934Abstract: The present invention relates to pseudotyped retrovirus-like particles or retroviral vectors comprising both engineered envelope glycoproteins derived from a virus of the Paramyxoviridae family fused to a cell targeting domain and fused to a functional domain. The present invention also relates to the use of said pseudotyped retrovirus-like particles or retroviral vectors to selectively modulate the activity of specific subsets of cells, in particular of specific immune cells. These pseudotyped retrovirus-like particles or retroviral vectors are particularly useful for gene therapy, immune therapy and/or vaccination.Type: ApplicationFiled: March 6, 2023Publication date: November 2, 2023Applicants: Ecole Normale Superieure de Lyon, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1, Institut National de la Santé et de la Recherche Medicale (INSERM), Centre National de la Recherche ScientifiqueInventors: Caroline COSTA FEJOZ, Els Verhoeyen, François-Loîc Cosset, Ruben Bender, Christian Buchholz, Qi Zhou
-
Patent number: 11801400Abstract: A therapy apparatus for treating tissue by emission of focused ultrasound waves, including: a creation surface of a pressure field of focused ultrasound waves divided into at least N sectors having segments of asymmetrical concave curve with centres of curvature; centres of curvature asymmetrical to the extent where the centres of curvature are situated at different distances from the plane of symmetry or from at least one of the axis of symmetry and at different depths taken according to the axis of symmetry; the individual axes intersecting between the focal zones and the creation surface or beyond the focal zones such that the beams originating from the sectors intersect to create a focal coverage zone which is off-axis relative to the plane of symmetry or to the axis of symmetry; the sectors of this creation surface creating energy deposit zones with profiles corresponding to the focal coverage zones.Type: GrantFiled: April 1, 2021Date of Patent: October 31, 2023Assignees: EDAP TMS FRANCE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDECALE (INSERM), UNIVERSITE CLAUDE BERNARD LYON 1, CENTRE LEON BERARDInventors: Marine Sanchez, David Melo De Lima, Jérémy Vincenot
-
Patent number: 11795144Abstract: The present invention concerns a compound having the following formula (I): wherein: A is in particular —N(R?a)—C(?O)—R, R?a being H or a (C1-C6)alkyl group, and R being preferably a group having the following formula (II): X is in particular chosen from the group consisting of: —SO2—N(R?b)—, R?b being H or a (C1-C6)alkyl group, —N(R?b)—SO2—, R?b being H or a (C1-C6)alkyl group, —CO—NH—, and —NH—CO—, for use for the treatment of cancers, such as metastatic cancers.Type: GrantFiled: June 6, 2018Date of Patent: October 24, 2023Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, CHU NANTESInventors: Vincent Sauzeau, Gervaise Loirand, Jacques Lebreton, Arnaud Tessier, Agnès Quemener
-
Patent number: 11793865Abstract: A composition including a supernatant obtained from co-culture of phagocytes with apoptotic cells. The composition is obtained by a) providing phagocytes, b) providing apoptotic cells, c) optionally washing the cells from step a) and b), d) co-culturing the cells of step a) and b), and e) separating the supernatant from the cells. The composition may be used in preventing or treating a pathological immune response.Type: GrantFiled: April 14, 2020Date of Patent: October 24, 2023Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ETABLISSEMENT FRANCAIS DU SANG, UNIVERSITE DE FRANCHE-COMTE, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE BESANCONInventors: Sylvain Perruche, Philippe Saas, Francis Bonnefoy